Suppr超能文献

通过造血祖细胞转导将独特的短发夹 RNA 递送至巨噬细胞中,抑制趋化因子受体 5 对 HIV-1 的感染。

Inhibition of HIV-1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transduction.

机构信息

Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA.

出版信息

J Gene Med. 2010 Mar;12(3):255-65. doi: 10.1002/jgm.1440.

Abstract

BACKGROUND

We recently expressed a potent and noncytotoxic short hairpin (sh)RNA directed against chemokine (c-c motif) receptor 5 (CCR5) using lentiviral mediated transduction of CD34+ hematopoietic progenitor cells (HPCs) and demonstrated the stable reduction of CCR5 expression in T-lymphocytes.

METHODS

In the present study, we further assessed the activity of the shRNA through HPC transduction and differentiation into macrophages derived from fetal liver CD34+ (FL-CD34+) HPCs. Transduced lentiviral vector encoding the human CCR5 shRNA was stably maintained in FL-CD34+ cells and in the terminally differentiated macrophages using macrophage colony-stimulating factor, granulocyte macrophage colony-stimulating factor, interleukin-3 and stem cell factor.

RESULTS

Quantitative real-time polymerase chain reaction for CCR5 mRNA indicated over 90% reduction of CCR5 mRNA levels in CCR5 shRNA-transduced population. The cells with knockdown of CCR5 expression acquired resistance to R5 tropic HIV-1 NFN-SX strain. We also developed a novel approach utilizing a mCherry-CCR5 chimeric reporter to assess the effectiveness of CCR5 target down-regulation in macrophages directly. Both the shRNA and the reporter were maintained throughout HPC differentiation to macrophages without apparent cytotoxicity.

CONCLUSIONS

The present study demonstrates a novel method to simply and directly assess the function of small interfering RNA and the effective inhibition of HIV-1 infection by a potential potent shRNA to CCR5 delivered into macrophages derived from HPCs.

摘要

背景

我们最近使用慢病毒介导的转导 CD34+造血祖细胞(HPC)表达了一种针对趋化因子(c-c 基序)受体 5(CCR5)的有效且非细胞毒性的短发夹(sh)RNA,并证明了 T 淋巴细胞中 CCR5 表达的稳定降低。

方法

在本研究中,我们通过 HPC 转导和分化为来自胎儿肝脏 CD34+(FL-CD34+)HPC 的巨噬细胞进一步评估了 shRNA 的活性。转导的慢病毒载体编码人 CCR5 shRNA,在使用巨噬细胞集落刺激因子、粒细胞巨噬细胞集落刺激因子、白细胞介素 3 和干细胞因子的 FL-CD34+细胞和终末分化的巨噬细胞中稳定维持。

结果

CCR5 mRNA 的定量实时聚合酶链反应表明,CCR5 shRNA 转导群体中的 CCR5 mRNA 水平降低了 90%以上。表达 CCR5 下调的细胞对 R5 嗜性 HIV-1 NFN-SX 株获得了抗性。我们还开发了一种新方法,利用 mCherry-CCR5 嵌合报告基因来直接评估巨噬细胞中 CCR5 靶基因下调的有效性。shRNA 和报告基因在整个 HPC 分化为巨噬细胞的过程中均得以维持,且没有明显的细胞毒性。

结论

本研究证明了一种新的方法,可以简单直接地评估小干扰 RNA 的功能,以及通过潜在有效的 CCR5 shRNA 直接递送至源自 HPC 的巨噬细胞中,有效地抑制 HIV-1 感染。

相似文献

3
Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy.
AIDS Res Hum Retroviruses. 2001 Mar 20;17(5):385-99. doi: 10.1089/088922201750102427.
4

引用本文的文献

1
Cytokines as emerging regulators of central nervous system synapses.
Immunity. 2023 May 9;56(5):914-925. doi: 10.1016/j.immuni.2023.04.011.
2
The first genetically gene-edited babies: It's "irresponsible and too early".
Animal Model Exp Med. 2019 Jan 11;2(1):1-4. doi: 10.1002/ame2.12052. eCollection 2019 Mar.
3
Gene Therapy Approaches to Functional Cure and Protection of Hematopoietic Potential in HIV Infection.
Pharmaceutics. 2019 Mar 11;11(3):114. doi: 10.3390/pharmaceutics11030114.
4
The latest evidence for possible HIV-1 curative strategies.
Drugs Context. 2018 Feb 21;7:212522. doi: 10.7573/dic.212522. eCollection 2018.
5
Modeling Anti-HIV-1 HSPC-Based Gene Therapy in Humanized Mice Previously Infected with HIV-1.
Mol Ther Methods Clin Dev. 2017 Dec 1;9:23-32. doi: 10.1016/j.omtm.2017.11.008. eCollection 2018 Jun 15.
6
CRISPR Genome Engineering for Human Pluripotent Stem Cell Research.
Theranostics. 2017 Oct 7;7(18):4445-4469. doi: 10.7150/thno.18456. eCollection 2017.
7
Prospects for Foamy Viral Vector Anti-HIV Gene Therapy.
Biomedicines. 2016 Mar 29;4(2):8. doi: 10.3390/biomedicines4020008.
8
CCR5 is a suppressor for cortical plasticity and hippocampal learning and memory.
Elife. 2016 Dec 20;5:e20985. doi: 10.7554/eLife.20985.
9
C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection.
Appl Transl Genom. 2013 May 26;2:3-16. doi: 10.1016/j.atg.2013.05.004. eCollection 2013 Dec 1.
10
The feasibility of incorporating Vpx into lentiviral gene therapy vectors.
Mol Ther Methods Clin Dev. 2016 Oct 19;5:16066. doi: 10.1038/mtm.2016.66. eCollection 2016.

本文引用的文献

1
Characterization of a potent non-cytotoxic shRNA directed to the HIV-1 co-receptor CCR5.
Genet Vaccines Ther. 2009 Jun 10;7:8. doi: 10.1186/1479-0556-7-8.
2
Reassessing the role of APOBEC3G in human immunodeficiency virus type 1 infection of quiescent CD4+ T-cells.
PLoS Pathog. 2009 Mar;5(3):e1000342. doi: 10.1371/journal.ppat.1000342. Epub 2009 Mar 20.
3
Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.
N Engl J Med. 2009 Feb 12;360(7):692-8. doi: 10.1056/NEJMoa0802905.
4
Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates.
Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13110-5. doi: 10.1073/pnas.0705474104. Epub 2007 Aug 1.
6
Predictors of disease progression in HIV infection: a review.
AIDS Res Ther. 2007 May 14;4:11. doi: 10.1186/1742-6405-4-11.
7
Chemokine antagonists as therapeutics: focus on HIV-1.
Annu Rev Med. 2007;58:445-59. doi: 10.1146/annurev.med.58.080105.102908.
8
The virion-associated incoming HIV-1 RNA genome is not targeted by RNA interference.
Retrovirology. 2006 Sep 4;3:57. doi: 10.1186/1742-4690-3-57.
9
Toxicity in mice expressing short hairpin RNAs gives new insight into RNAi.
Genome Biol. 2006;7(8):231. doi: 10.1186/gb-2006-7-8-231.
10
Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors.
Mol Ther. 2006 Oct;14(4):494-504. doi: 10.1016/j.ymthe.2006.05.015. Epub 2006 Jul 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验